Research programme: complement system protein inhibitors - BMS
Latest Information Update: 08 Dec 2015
At a glance
- Originator iPierian
- Developer Bristol-Myers Squibb; iPierian
- Class Monoclonal antibodies
- Mechanism of Action Complement C1s inhibitors; Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune haemolytic anaemia; Cardiovascular disorders; Immunological disorders; Metabolic disorders; Neurodegenerative disorders